Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation

Clinical and Vaccine Immunology

Volumn 18, Issue 9, 2011, Pages 1577-1581

  Hallengärd, David ^a   Haller, B Kristian ^a   Maltais, Anna Karin ^b   Gelius, Eva ^c   Nihlmark, Kopek ^c   Wahren, Britta ^a   Bråve, Andreas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Cyto Pulse Sciences Inc   (United States)

^c Mabtech ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; PLASMID DNA; PROTEIN P37; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ANIMALS; ELECTROPORATION; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, DNA;

EID: 80052436125     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05045-11     Document Type: Article

References (29)

1. Almeida, J. R., et al. 2007. Superior control of HIV-1 replication by CD8+T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204:2473-2485. (Pubitemid 47529331)
2. Babiuk, S., M. Baca-Estrada, L. A. Babiuk, C. Ewen, and M. Foldvari. 2000. Cutaneous vaccination: The skin as an immunologically active tissue and the challenge of antigen delivery. J. Control. Release 66:199-214. (Pubitemid 30160857)
3. Bergman, P. J., et al. 2006. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24:4582-4585. (Pubitemid 44218845)
4. Betts, M. R., et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789. (Pubitemid 43882629)
5. Brave, A., et al. 2010. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 28:8203-8209.
6. Brave, A., et al. 2009. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. Vaccine 27:3692-3696.
7. Brave, A., et al. 2005. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol. Ther. 12:1197-1205. (Pubitemid 41723054)
8. Buchan, S., et al. 2005. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 174:6292-6298. (Pubitemid 40663821)
9. Davis, B. S., et al. 2001. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75:4040-4047. (Pubitemid 32410116)
10. Gothelf, A., J. Eriksen, P. Hojman, and J. Gehl. 2010. Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Ther. 17:839-845.
11. Hallengärd, D., et al. 2011. Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29:839-848.
12. Hirao, L. A., et al. 2011. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J. Infect. Dis. 203:95-102.
13. Hirao, L. A., et al. 2008. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 26:3112-3120.
14. Hirao, L. A., et al. 2010. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol. Ther. 18:1568-1576.
15. Hojman, P., H. Gissel, and J. Gehl. 2007. Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther. 14:950-959. (Pubitemid 46865506)
16. Kanitakis, J. 2002. Anatomy, histology and immunohistochemistry of normal human skin. Eur. J. Dermatol. 12:390-399.
17. Kutzler, M. A., and D. B. Weiner. 2008. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 9:776-788.
18. Laddy, D. J., et al. 2009. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83:4624-4630.
19. Liu, J., R. Kjeken, I. Mathiesen, and D. H. Barouch. 2008. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82:5643-5649. (Pubitemid 351705271)
20. Lorenzen, N., and S. E. LaPatra. 2005. DNA vaccines for aquacultured fish. Rev. Sci. Tech. 24:201-213. (Pubitemid 41112540)
21. Low, L., et al. 2009. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum. Gene Ther. 20: 1269-1278.
22. McCluskie, M. J., et al. 1999. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5:287-300. (Pubitemid 29342964)
23. Quast, S., et al. 2005. IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. Cell. Immunol. 237:28-36. (Pubitemid 41821079)
24. Roos, A. K., et al. 2009. Skin electroporation: Effects on transgene expression, DNA persistence and local tissue environment. PLoS One 4:e7226.
25. Sandstrom, E., et al. 2008. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490.
26. Schwartz, S., B. K. Felber, and G. N. Pavlakis. 1992. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J. Virol. 66:150-159.
27. Tsang, C., S. Babiuk, S. Van Drunen Littel-van den Hurk, L. A. Babiuk, and P. Griebel. 2007. A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine 25:5485-5494. (Pubitemid 47039264)
28. Vasan, S., et al. 2011. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6:e19252.
29. Yang, Z. Y., et al. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77:799-803.